Ivivi Technologies receives EU approval for electrotherapy devices

11 July 2007

Northvale. USA. Ivivi Technologies, Inc. (AMEX:II), a leader in non-invasive, electrotherapeutic technologies, today announced that it has received CE Mark certification for the commercial distribution of certain of its patented electrotherapy devices, in the member countries of the European Union, for use in the promotion of wound healing, reduction of pain and post operative edema.

“Obtaining the CE approval is a significant milestone for our company in our efforts to commercialize our non-invasive electrotherapeutic technology throughout Europe,” said André DiMino, Co-CEO, Ivivi Technologies. “It supports our strategy of establishing channel partnerships with global medical device and healthcare companies.”

Ivivi’s electrotherapy devices consist of a signal generator and applicator and are programmed to provide therapy at optimal intervals throughout the course of therapy. As previously announced, a recent study conducted at Akademikliniken Hospital in Stockholm, Sweden by Dr. Per Heden, an internationally-recognized plastic surgeon and researcher, reinforced clinical data that shows the ability of Ivivi’s technology to enhance post-surgical pain management.

Preliminary data from a randomized double-blind, placebo-controlled clinical study entitled “Effect of Pulsed Electromagnetic Fields (“PEMF”) on Post-Surgical Pain Reduction for Breast Augmentation” showed an 80% acceleration in pain relief in patients treated with the active technology as compared to patients treated with placebo units.

To top